88.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$88.75
Offen:
$88.82
24-Stunden-Volumen:
8.66M
Relative Volume:
1.13
Marktkapitalisierung:
$112.76B
Einnahmen:
$33.54B
Nettoeinkommen (Verlust:
$4.66B
KGV:
24.39
EPS:
3.62
Netto-Cashflow:
$5.19B
1W Leistung:
+2.69%
1M Leistung:
+5.42%
6M Leistung:
+10.05%
1J Leistung:
+14.10%
Medtronic Plc Stock (MDT) Company Profile
Firmenname
Medtronic Plc
Sektor
Branche
Telefon
01135314381700
Adresse
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Vergleichen Sie MDT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
2025-03-04 | Hochstufung | Citigroup | Neutral → Buy |
2024-10-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-08-21 | Bestätigt | Oppenheimer | Perform |
2024-08-15 | Hochstufung | UBS | Sell → Neutral |
2024-08-14 | Herabstufung | Stifel | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Sell |
2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
2023-06-30 | Eingeleitet | CL King | Buy |
2023-05-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-29 | Herabstufung | UBS | Buy → Sell |
2023-01-09 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-11-23 | Herabstufung | Citigroup | Buy → Neutral |
2022-11-23 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
2022-10-18 | Eingeleitet | Barclays | Equal Weight |
2022-10-13 | Eingeleitet | Mizuho | Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-08-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
2022-06-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
2022-05-27 | Herabstufung | Needham | Buy → Hold |
2022-04-13 | Herabstufung | Truist | Buy → Hold |
2022-03-02 | Fortgesetzt | BofA Securities | Buy |
2022-01-10 | Herabstufung | BTIG Research | Buy → Neutral |
2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-12-16 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-06-10 | Fortgesetzt | Cowen | Outperform |
2021-05-25 | Eingeleitet | Barclays | Equal Weight |
2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
2020-12-15 | Hochstufung | Goldman | Sell → Neutral |
2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-10-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2020-10-08 | Hochstufung | Stifel | Hold → Buy |
2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
2020-05-14 | Herabstufung | DZ Bank | Buy → Hold |
2020-03-30 | Herabstufung | Needham | Strong Buy → Buy |
2020-03-25 | Hochstufung | DZ Bank | Hold → Buy |
2020-03-05 | Eingeleitet | Citigroup | Buy |
2020-02-13 | Eingeleitet | Goldman | Sell |
2020-01-08 | Eingeleitet | SunTrust | Buy |
2020-01-02 | Hochstufung | Guggenheim | Neutral → Buy |
2019-06-05 | Hochstufung | Wells Fargo | Market Perform → Outperform |
2019-02-04 | Bestätigt | Needham | Strong Buy |
2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
2019-01-02 | Herabstufung | Citigroup | Buy → Neutral |
2018-12-19 | Hochstufung | JP Morgan | Neutral → Overweight |
2018-11-28 | Eingeleitet | UBS | Buy |
2018-10-16 | Eingeleitet | Barclays | Overweight |
2018-08-27 | Bestätigt | Argus | Buy |
Alle ansehen
Medtronic Plc Aktie (MDT) Neueste Nachrichten
Medtronic Diabetes and tennis pro Alexander Zverev join forces to champion life without limits for people with diabetes - Medtronic
Medtronic training pact includes Hugo robot, cardiac ablation tech - MedTech Dive
Medtronic stock has significant opportunity in renal denervation, RBC says By Investing.com - Investing.com UK
FDA Clears Minimally Invasive Laser Ablation System from Medtronic for Epilepsy & Brain Tumors - Medical Device and Diagnostic industry
Medtronic partners with IRCAD on Hugo, Affera surgical training - MassDevice
Medtronic to invest $50 million over five years in Pune GCC - BusinessLine
Medtronic : IRCAD North America and Medtronic announce collaboration to advance surgical training and innovation - MarketScreener
Surgical Retractors Market Top Companies StudyMedtronic Plc, - openPR.com
Medtronic to invest $50 million over 5 years in Pune - PUNE PULSE
Medtronic plc Stock MDT Using Cash Flow Model NYSE Composite - Kalkine Media
A Look At The Fair Value Of Medtronic plc (NYSE:MDT) - simplywall.st
Medtronic to invest $50 million over 5 years in New Diabetes Global Capability Centre in Pune - Punekar News
Medtronic Invests $50M in Pune Diabetes Center - Rediff MoneyWiz
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Nigeria
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings By Investing.com - Investing.com South Africa
Leerink Partners Initiates Coverage on Medtronic (MDT) with Outperform Rating | MDT Stock News - GuruFocus
Medtronic (MDT) Positioned for Growth Amid Strategic Shifts | MDT Stock News - GuruFocus
Leerink Partners Initiates Medtronic at Outperform With $110 Price Target - MarketScreener
Medtronic: Solid Recent Performance But Better Options Available (NYSE:MDT) - Seeking Alpha
Medtronic Doubles Down on Innovation as Cardiovascular Tech Takes Center Stage! - Smartkarma
Medtronic’s SWOT analysis: stock outlook amid diabetes spin-off and RDN growth - Investing.com
Medtronic separate diabetes business to be called MiniMed - MSN
Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst - Benzinga
FDA approves Medtronic Omniasecure defib lead - BioWorld MedTech
Medtronic Plc. (NYSE: MDT) To Separate Its Diabetes Business - Smartkarma
Earnings Preview: What To Expect From Medtronic’s Report - MSN
Medtronic Diabetes Spinoff to Honor MiniMed Roots - Medical Device and Diagnostic industry
Medtronic (MDT) Revives MiniMed for Diabetes Spin-Off - GuruFocus
Medtronic recalls ventilators linked to 2 serious injuries, 1 death - MedTech Dive
Medtronic issues safety notice for Hugo surgical robot console in Europe - MassDevice
Medtronic announces MiniMed as name for planned New Diabetes Company - GuruFocus
Medtronic (MDT) Unveils "MiniMed" for Upcoming Diabetes Spinoff - GuruFocus
Medtronic's New Diabetes Company to Be Named MiniMed - MarketScreener
Medtronic announces MiniMed as name for planned New Diabetes Company | MDT Stock News - GuruFocus
Medtronic names planned diabetes spinoff company MiniMed - Investing.com
Medtronic names planned diabetes spinoff company MiniMed By Investing.com - Investing.com Canada
Medtronic Announces MiniMed As Name For Planned New Diabetes Company - marketscreener.com
FDA Upgrades Medtronic Recall Of Newport Ventilators To Class I - RTTNews
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market - MSN
Medtronic advises discontinuation of certain Newport ventilators after recall - MassDevice
Medtronic : announces voluntary recall of select Newport™ HT70 and Newport™ HT70 Plus ventilators and certain related Newport™ service parts - marketscreener.com
Medtronic : treats first U.S. patient in Global SYMPLICITY Registry DEFINE Study - marketscreener.com
5 Things You Need to Know If You Buy Medtronic Today - The Motley Fool
Medtronic names Kate Benedict president of acute care and monitoring - MedTech Dive
Medtronic appoints new president of Acute Care & Monitoring unit - MassDevice
Medtronic Announces Intent To Spin Diabetes Business - Forbes
Medtronic wins CE mark for VitalFlow ECMO system - MassDevice
Medtronic to separate diabetes business, WSJ reports - MSN
Medtronic's Separation of Diabetes Business May Drive Long-Term Value, Needham Says - marketscreener.com
Medtronic removes tracheostomy tubes due to dislodging risk - MedTech Dive
NEEDHAM ANALYST MAINTAINS HOLD RATING ON MEDTRONIC STOCK By Investing.com - Investing.com UK
Finanzdaten der Medtronic Plc-Aktie (MDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Medtronic Plc-Aktie (MDT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Walter Matthew R. | SVP, Chief HR Officer |
Jan 27 '25 |
Option Exercise |
74.84 |
1,337 |
100,061 |
26,997 |
Marinaro Michael | EVP & President, Surgical OU |
Jan 27 '25 |
Option Exercise |
74.84 |
2,345 |
175,500 |
43,323 |
Martha Geoffrey | Chairman and CEO |
Jan 27 '25 |
Option Exercise |
74.84 |
34,741 |
2,600,016 |
216,954 |
Wall Brett A. | EVP & Pres Neuroscience |
Jan 24 '25 |
Option Exercise |
78.00 |
12,437 |
970,086 |
53,416 |
Wall Brett A. | EVP & Pres Neuroscience |
Jan 24 '25 |
Sale |
90.00 |
12,437 |
1,119,330 |
40,979 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):